<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37356347</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9157</ISSN><JournalIssue CitedMedium="Internet"><Volume>139</Volume><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of autoimmunity</Title><ISOAbbreviation>J Autoimmun</ISOAbbreviation></Journal><ArticleTitle>Extracellular vesicles opsonized by monomeric C-reactive protein (CRP) are accessible as autoantigens in patients with systemic lupus erythematosus and associate with autoantibodies against CRP.</ArticleTitle><Pagination><StartPage>103073</StartPage><MedlinePgn>103073</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaut.2023.103073</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-8411(23)00082-3</ELocationID><Abstract><AbstractText>The pentraxin C-reactive protein (CRP) is a pentameric protein now known to be able to undergo dissociation into a monomeric, modified isoform, referred to as mCRP. In carefully assessing the bioactivities of each isoform, mCRP has strong pro-inflammatory activities while pCRP has mild anti-inflammatory activities. Systemic lupus erythematosus (SLE) is a disease characterized by a vast number of autoantibodies, including anti-CRP autoantibodies which have been associated with SLE disease activity and lupus nephritis. The origin of these autoantibodies is currently unknown. Extracellular vesicles (EVs) have been implicated in SLE pathogenesis as they can expose nuclear antigens on their outside surface, thereby being a potential adjuvant for the generation of autoantibodies. Herein, we studied exposure of both pCRP and mCRP on EVs in SLE plasma and the implications of each in disease activity, organ damage and clinical manifestations. We used flow cytometry to detect CRP isoforms on EV surfaces in 67 well-characterized SLE patients and 60 sex- and age-matched healthy controls. Autoantibodies against mCRP were measured using ELISA. We found an abundance of both pCRP and mCRP on SLE EVs compared to controls. Furthermore, mCRP<sup>+</sup> but not pCRP<sup>+</sup> EVs were elevated in patients with active disease and in anti-CRP positive patients. The proportions of mCRP<sup>+</sup> EVs were lower in patients with acquired organ damage, especially in patients with lupus nephritis (LN), and displayed an inverse relationship with disease duration in LN and patients with active disease. Speculatively, these data suggest EV-bound mCRP as a relevant factor in SLE pathogenesis, which could contribute to development of anti-CRP autoantibodies by stimulating an immune response.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karlsson</LastName><ForeName>Jesper</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, Division of Inflammation &amp; Infection, Link&#xf6;ping University, Link&#xf6;ping, Sweden. Electronic address: jesper.karlsson@liu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wetter&#xf6;</LastName><ForeName>Jonas</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, Division of Inflammation &amp; Infection, Link&#xf6;ping University, Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Potempa</LastName><ForeName>Lawrence A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Roosevelt University, College of Science, Health and Pharmacy, Schaumburg, IL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez-Botran</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology &amp; Laboratory Medicine, University of Louisville, Louisville, KY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Neill</LastName><ForeName>Yasmine</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, Division of Clinical Chemistry, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wirestam</LastName><ForeName>Lina</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, Division of Inflammation &amp; Infection, Link&#xf6;ping University, Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mobarrez</LastName><ForeName>Fariborz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, Division of Clinical Chemistry, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sj&#xf6;wall</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, Division of Inflammation &amp; Infection, Link&#xf6;ping University, Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Autoimmun</MedlineTA><NlmUniqueID>8812164</NlmUniqueID><ISSNLinking>0896-8411</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001324" MajorTopicYN="N">Autoantigens</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067128" MajorTopicYN="Y">Extracellular Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-CRP antibodies</Keyword><Keyword MajorTopicYN="N">C-reactive protein</Keyword><Keyword MajorTopicYN="N">Extracellular vesicles</Keyword><Keyword MajorTopicYN="N">Immune complexes</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>Declaration of competing interest None to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>26</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>25</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37356347</ArticleId><ArticleId IdType="doi">10.1016/j.jaut.2023.103073</ArticleId><ArticleId IdType="pii">S0896-8411(23)00082-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>